Edition:
United Kingdom

Tigenix NV (G9U.BR)

G9U.BR on Brussels Stock Exchange

1.07EUR
15 Dec 2017
Change (% chg)

€0.14 (+15.19%)
Prev Close
€0.93
Open
€0.97
Day's High
€1.19
Day's Low
€0.95
Volume
18,400,829
Avg. Vol
797,361
52-wk High
€1.19
52-wk Low
€0.64

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency Recommendations For December 2017 ‍​
12:19pm GMT 

Dec 15 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDATIONS FOR DECEMBER 2017 ‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF NOVO NORDISK'S ONCE-WEEKLY DIABETES DRUG SEMAGLUTIDE‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF KYOWA HAKKO KIRIN DRUG FOR GENETIC BLOOD DISORDER XLH BUROSUMAB.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TIGENIX'S STEM CELLS TREATMENT FOR PERIANAL FISTULAS ALOFISEL.  Full Article

Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion
12:11pm GMT 

Dec 15 (Reuters) - TIGENIX NV ::REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE.‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​.‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​.‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​.  Full Article

Tigenix Announces Grant From Mesoblast Of Exclusive Global Patent License In Local Treatment Of Fistulae
7:32am GMT 

Dec 15 (Reuters) - Tigenix Nv ::MESOBLAST GRANTS TIGENIX AN EXCLUSIVE GLOBAL PATENT LICENSE TO USE ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN THE LOCAL TREATMENT OF FISTULAE (EN).AGREEMENT INCLUDES RIGHT FOR CO TO GRANT SUB-LICENSES TO AFFILIATES AND THIRD PARTIES.MESOBLAST WILL RECEIVE SINGLE DIGIT ROYALTIES ON NET SALES OF CX601.MESOBLAST WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS.  Full Article

Mesoblast Says Granted Tigenix Access To Certain Of Its Patents
Thursday, 14 Dec 2017 

Dec 15 (Reuters) - Mesoblast Ltd ::CO WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS ​.‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​.  Full Article

JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​
Saturday, 25 Nov 2017 

Nov 24 (Reuters) - Tigenix Nv :‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​.  Full Article

Tigenix announces partial conversion of bonds
Monday, 6 Nov 2017 

Nov 6 (Reuters) - TIGENIX NV : :‍ANNOUNCES CONVERSION OF EUR 7 MILLION OF COMPANY'S SENIOR UNSECURED CONVERTIBLE BONDS DUE 2018​.‍THROUGH CONVERSION, TOTAL CONVERTIBLE DEBT OUTSTANDING REDUCED FROM EUR 25 MILLION TO EUR 18 MILLION​.‍TO ISSUE 7,792,496 SHARES IN EXCHANGE FOR THE CONVERTED BONDS​.‍SHARE EXPECTED TO BE ISSUED ON OR AROUND 10 NOVEMBER 2017​.  Full Article

Tigenix obtains patent for Cx601 lead development program
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - TIGENIX NV ::REG-TIGENIX STRENGTHENS EUROPEAN IP PROTECTION AROUND LEAD DEVELOPMENT PROGRAM CX601.‍THIS PATENT PROTECTION GRANTS PRODUCT 10 YEARS OF MARKET EXCLUSIVITY FOLLOWING MARKETING APPROVAL IN EUROPE​.‍SUBMITTED A MARKETING AUTHORIZATION (MA) APPLICATION TO EMA, WHEREFORE A CHMP OPINION IS EXPECTED TO BE RECEIVED IN 2017​.  Full Article

TiGenix provides update on Cx601 marketing authorization application
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - TIGENIX NV ::REG-TIGENIX PROVIDES REGULATORY UPDATE ON CX601 EU MARKETING AUTHORIZATION APPLICATION PROCEDURE.‍PROVIDED AN ORAL EXPLANATION OF ITS RESPONSES TO CX601 MARKETING AUTHORIZATION​.  Full Article

Tigenix granted orphan drug designation from the U.S. FDA for CX601
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Tigenix Nv :Tigenix granted orphan drug designation from the U.S. FDA for cx601.‍exploring expedited pathways to accelerate submission and review process for U.S. Regulatory approval​.  Full Article

TiGenix granted orphan drug designation from FDA for CX601
Monday, 23 Oct 2017 

Oct 23 (Reuters) - TIGENIX NV ::REG-TIGENIX GRANTED ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR CX601.  Full Article

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE